The chemical substance known as "eeAChE/eqBuChE-IN-1" with the CAS number "2921654-26-2" is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), enzymes that play crucial roles in the hydrolysis of the neurotransmitter acetylcholine. This compound is of interest in pharmacological research, particularly in the context of neurodegenerative diseases such as Alzheimer's, where the modulation of cholinergic activity is a therapeutic target. The structure of eeAChE/eqBuChE-IN-1 typically features functional groups that enhance its binding affinity to the active sites of these enzymes, thereby inhibiting their activity. Its specificity for AChE and BuChE can lead to potential applications in enhancing cognitive function or managing symptoms associated with cholinergic dysfunction. Additionally, the compound's pharmacokinetic properties, such as solubility, stability, and bioavailability, are critical for its development as a therapeutic agent. Further studies are necessary to fully understand its efficacy, safety profile, and potential side effects in clinical settings.

eeAChE/eqBuChE-IN-1

2921654-26-2: The chemical substance known as "eeAChE/eqBuChE-IN-1" with the CAS number "2921654-26-2" is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), enzymes that play crucial roles in the hydrolysis of the neurotransmitter acetylcholine. This compound is of interest in pharmacological research, particularly in the context of neurodegenerative diseases such as Alzheimer's, where the modulation of cholinergic activity is a therapeutic target. The structure of eeAChE/eqBuChE-IN-1 typically features functional groups that enhance its binding affinity to the active sites of these enzymes, thereby inhibiting their activity. Its specificity for AChE and BuChE can lead to potential applications in enhancing cognitive function or managing symptoms associated with cholinergic dysfunction. Additionally, the compound's pharmacokinetic properties, such as solubility, stability, and bioavailability, are critical for its development as a therapeutic agent. Further studies are necessary to fully understand its efficacy, safety profile, and potential side effects in clinical settings.

<p>eeAChE/eqBuChE-IN-1 (compound 3F) serves as a reversible dual inhibitor of eeAChE/eqBuChE, exhibiting IC50 values of 1.3 μM and 0.81 μM, respectively. In addition, this compound demonstrates anti-inflammatory properties and provides neuroprotective effects against Aβ25-35-induced injury in PC12 cells [1].</p>

CAS 2921654-26-2

eeAChE/eqBuChE-IN-1

eeAChE/eqBuChE-IN-1

Ref: TM-T86340